Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: A phase I clinical trial
Số trang: 9
Loại file: pdf
Dung lượng: 1.45 MB
Lượt xem: 10
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Conquering acquired resistance to osimertinib remains a major challenge in treating patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Thus, we aimed to determine the safety and efcacy of combination treatment with osimertinib and afatinib for patients with acquired resistance to osimertinib.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Adverse event Epidermal growth factor receptor Maximum tolerated dose Resistance mechanism Synergistic effectGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 169 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 110 0 0 -
12 trang 87 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 36 0 0
-
11 trang 35 0 0
-
12 trang 34 0 0